Page Not Found
You asked for http://www.2.clinuvel.com/en/clinuvel/itemlist/tag/epp, but despite our computers looking very hard, we could not find it. What happened ?
- the link you clicked to arrive here has a typo in it
- or somehow we removed that page, or gave it another name
- or, quite unlikely for sure, maybe you typed it yourself and there was a little mistake ?
It's not the end of everything though : you may be interested in the following pages on our site:
Clinuvel Blog Posts
“Basal cell carcinoma skin cancer is the most common form of skin cancer”. It’s a common claim and one which is undoubtedly true –...
Read More
Earlier today we announced that two health insurers in Switzerland had agreed to reimburse SCENESSE® (afamelanotide) for the rare disease...
Read More
In a letter published this week in the British Journal of Medicine three dermatologists have highlighted the potential risks posed by the...
Read MoreClinuvel Webcasts
Vitiligo is a skin disorder which causes the loss of pigment - melanin - in the skin. Though it affects around 45 million people worldwide,... Watch now |
On 31 January 2012 Swiss TV channel Telezueri aired a report on erythropoietic protoporphyria (EPP), a rare genetic disorder which causes ab... Watch now |
Following Clinuvel's landmark filing of a marketing authorisation application for the drug SCENESSE® (afamelanotide) with the European Medic... Watch now |
Clinuvel Spotlight
The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an... Read more |
